表紙
市場調査レポート

ベッカー型筋ジストロフィー:パイプライン製品の分析

Becker Muscular Dystrophy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321917
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
ベッカー型筋ジストロフィー:パイプライン製品の分析 Becker Muscular Dystrophy - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 46 Pages
概要

ベッカー型筋ジストロフィーは、遺伝性の神経変性疾患の一種で、随意筋に症状が現れます。疼痛や走行、跳躍、つま先立ちなどの動作困難、呼吸困難、認識障害などが症状としてあげられます。

当レポートでは、ベッカー型筋ジストロフィーに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ベッカー型筋ジストロフィーの概要

治療薬の開発

  • パイプライン製品:概要

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Milo Biotechnology LLC
  • PTC Therapeutics, Inc.
  • ReveraGen BioPharma, Inc.
  • Sarepta Therapeutics, Inc.
  • Sphaera Pharma Pvt. Ltd

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AAV1-FS-344
  • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD
  • ARM-210
  • ataluren
  • epicatechin
  • Small Molecule for Becker Muscular Dystrophy
  • vamorolone

最新のパイプライン製品情報

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8391IDB

Summary

Global Markets Direct's, 'Becker Muscular Dystrophy - Pipeline Review, H2 2016', provides an overview of the Becker Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy
  • The report reviews pipeline therapeutics for Becker Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Becker Muscular Dystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Becker Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Becker Muscular Dystrophy Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Becker Muscular Dystrophy - Overview 7
  • Becker Muscular Dystrophy - Therapeutics under Development by Companies 8
  • Becker Muscular Dystrophy - Pipeline Products Glance 9
  • Late Stage Products 9
  • Clinical Stage Products 10
  • Early Stage Products 11
  • Becker Muscular Dystrophy - Products under Development by Companies 12
  • Becker Muscular Dystrophy - Companies Involved in Therapeutics Development 13
  • Milo Biotechnology LLC 13
  • PTC Therapeutics, Inc. 14
  • ReveraGen BioPharma, Inc. 15
  • Sarepta Therapeutics, Inc. 16
  • Sphaera Pharma Pvt. Ltd. 17
  • Becker Muscular Dystrophy - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Target 19
  • Assessment by Mechanism of Action 21
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Drug Profiles 27
  • AAV1-Foliistatin - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • ARM-210 - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • ataluren - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • epicatechin - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • Small Molecule for Becker Muscular Dystrophy - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • vamorolone - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Becker Muscular Dystrophy - Dormant Projects 44
  • Appendix 45
  • Methodology 45
  • Coverage 45
  • Secondary Research 45
  • Primary Research 45
  • Expert Panel Validation 45
  • Contact Us 45
  • Disclaimer 46

List of Tables

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Late Stage Development, H2 2016 9
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2016 13
  • Becker Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2016 14
  • Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2016 15
  • Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016 16
  • Becker Muscular Dystrophy - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 17
  • Assessment by Monotherapy Products, H2 2016 18
  • Number of Products by Stage and Target, H2 2016 20
  • Number of Products by Stage and Mechanism of Action, H2 2016 22
  • Number of Products by Stage and Route of Administration, H2 2016 24
  • Number of Products by Stage and Molecule Type, H2 2016 26
  • Becker Muscular Dystrophy - Dormant Projects, H2 2016 44

List of Figures

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy Products, H2 2016 18
  • Number of Products by Targets, H2 2016 19
  • Number of Products by Stage and Targets, H2 2016 19
  • Number of Products by Mechanism of Actions, H2 2016 21
  • Number of Products by Stage and Mechanism of Actions, H2 2016 21
  • Number of Products by Routes of Administration, H2 2016 23
  • Number of Products by Stage and Routes of Administration, H2 2016 23
  • Number of Products by Molecule Types, H2 2016 25
  • Number of Products by Stage and Molecule Types, H2 2016 25
Back to Top